United Therapeutics Corporation announced today it has acquired Thymmune Therapeutics, Inc., a privately held, preclinical-stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.

Mattias Hebrok, PhD, Audrey Parent, PhD,and Mark Anderson, PhD, are the lead UCSF inventors and contributors to Thymmune Therapeutics.

Read more